Reforms in the Greek pharmaceutical market during the financial crisis

Health Policy

Volumn 109, Issue 1, 2013, Pages 1-6

  Vandoros, Sotiris ^a   Stargardt, Tom ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Cost containment; Efficiency; Greece; Market regulation; Pharmaceutical policy

Indexed keywords

GENERIC DRUG;

ARTICLE; BIOEQUIVALENCE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; ECONOMIC RECESSION; GREECE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; LAW; PHARMACY; PRESCRIPTION; PROFIT; PUBLIC HEALTH; QUALITY CONTROL;

COST CONTROL; DRUG COSTS; DRUG INDUSTRY; ECONOMIC RECESSION; EXTERNAL DEBT; FINANCING, GOVERNMENT; GREECE; HEALTH CARE REFORM; HEALTH EXPENDITURES; HEALTH POLICY;

EID: 84870919541     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2012.08.016     Document Type: Article

References (42)

1. World Bank. World development indicators 2011, data.worldbank.org/indicator; 2011.
2. World Health Organisation Health for all database 2012, http://data.euro.who.int/hfadb/.
3. Ginsburg P.B. Controlling health care costs. The New England Journal of Medicine 2004, 351:1591-1593.
4. OECD OECD health data 2011 2011, http://www.oecd.org/.
5. Tsiantou V., Zavras D., Kousoulakou H., Geitona M., Kyriopoulos J. Generic medicines: Greek physicians perceptions and prescribing practices. Journal of Clinical Pharmacy and Therapeutics 2009, 34:547-554.
6. Yfantopoulos J. Pharmaceutical pricing and reimbursement reforms in Greece. European Journal of Health Economics 2008, 9:87-97.
7. Falagas M.E., Bliziotis I.A., Michalopoulos A., Sermaides G., Papaioannou V.E., Nikita D., et al. Effect of a policy for restriction of selected classes of antibiotics on antimicrobial drug cost and resistance. Journal of Chemotherapy 2007, 19:178-184.
8. IMS Market prognosis report 2011 2011, http://www.imshealth.com/.
9. European Commission DG Competition. Pharmaceutical sector inquiry final report 2009, ec.europa.eu; 2009.
10. Contiades X., Golna C., Souliotis K. Pharmaceutical regulation in Greece at the crossroad of change: economic, political and constitutional considerations for a new regulatory paradigm. Health Policy 2007, 82:116-129.
11. Federal Union of German Associations of Pharmacists. Zahlen, Daten, Fakten;; 2010. http://www.abda.de/.
12. Hellenic Statistical Authority Press release 2011 2011, http://www.statistics.gr/.
13. Kanavos P, Schurer W, Vogler S. The pharmaceutical distribution chain in European Union Final Report 2011: structure and impact on pharmaceutical prices. Brussels: European Commission DG Enterprise, ec.europa.eu; 2011.
14. Interviews with Professor of Medicine Ioannis Ioannides and former Associate Professor of Medicine Ioannis Papadopoulos " Kouti tis Pandoras" documentary, NET Greek TV channel, 20 January 2011. Available at http://www.koutipandoras.gr/%3Fp=4147.
15. " List of eleven " olympic winner" physicians has been sent to the Public Attorney" [in Greek], 26 January 2012. Available at: http://news.kathimerini.gr/4dcgi/_w_articles_ell_100042_26/02/2012_474067.
16. " The party with off-label prescribing" [in Greek]. " Ta Nea" newspaper, 4 July 2012. Available at http://www.tanea.gr/ellada/article/%3Faid=4735461.
17. " 5 obvious cases of fraud worth 88 million Euros" [in Greek]. " Ethnos" newspaper, 7 August 2010. Available at: http://www.ethnos.gr/article.asp%3Fcatid=22767%26subid=2%26pubid=23720948.
18. The 2008 annual report of the general inspector of public administration. Athens; 2009.
19. Liaropoulos L., Siskou O., Kaitelidou D., Theodorou M., Katistaras T. Informal payments in public hospitals in Greece. Health Policy 2008, 87(1):72-81.
20. Greek Government Gazette No 557B,; 2011. http://www.et.gr/.
21. Greek Government Gazette No 1231B,; 2011. http://www.et.gr/.
22. Greek Government Gazette No 31A,; 2011. Law 3918/2011. http://www.et.gr/.
23. Greek Government Gazette No 866B,; 2011. http://www.et.gr/.
24. Greek Ministry of Health Press release 29.07.2011 2011, http://www.yyka.gov.gr/.
25. Greek Ministry of Health Press release 14.11.2011 2011, http://www.yyka.gov.gr/.
26. General secretariat of social insurance 2012.
27. Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy 2004, 68:47-54.
28. Frank R., Salkever D. Generic entry and the pricing of pharmaceuticals. Journal of Economics & Management Strategy 1997, 6:75-90.
29. Vandoros S., Kanavos P. The generics paradox revisited: empirical evidence from regulated markets. Applied Economics 2013, 45(22):3230-3239.
30. Kanavos P., Seeley E., Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: evidence from Netherlands, Germany and Belgium 2004, European Commission DG Enterprise, Brussels, ec.europa.eu.
31. Blankart R, Stargardt T. Modelling the effects of preferred supplier contracts in post-patent drug markets: an empirical evaluation using a hierarchical market share attraction model. Working Paper 2012.
32. Stargardt T. Modelling pharmaceutical prices in Germany as a function of competition and regulation. Applied Economics 2011, 43:4515-4526.
33. Kanavos P., Costa-Font J., Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Economic Policy 2008, 23(55):499-544.
34. Kanavos P., Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Economics, Policy and Law 2011, 6:313-335.
35. Busse R., Schreyögg J., Henke K.D. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures?. International Journal of Health Planning and Management 2005, 20:329-349.
36. Drummond M., Jönsson B., Rutten F., Stargardt T. Obtaining value for money from pharmaceuticals: a comparison of reference pricing with health technology assessment. European Journal of Health Economics 2011, 12:263-271.
37. Leopold C., Vogler S., Mantel-Teeuwisse A.K., de Joncheere K., Leukens H.G.M., Laing R. Differences in external price referencing in Europe: a descriptive overview. Health Policy 2012, 104(1):50-60.
38. Stargardt T., Schreyögg J. The impact of cross-reference pricing on pharmaceutical prices - manufacturers' pricing strategies and price regulation. Applied Health Economics and Health Policy 2006, 5(4):235-247.
39. Kathimerini newspaper 12 June 2010. 'Compromise keeps Novo Nordisk in Greece. Greece' [in Greek], http://news.kathimerini.gr/4dcgi/_w_articles_economy_2_12/06/2010_404232.
40. Kathimerini newspaper 26 September 2010. 'Artificial drug shortages because of exporting', http://news.kathimerini.gr/4dcgi/_w_articles_ell_1_26/09/2010_416463.
41. Kathimerini newspaper 12 October 2008. 'A present of 140 million to the pharmaceutical industry' [in Greek], http://news.kathimerini.gr/4dcgi/_w_articles_politics_2_12/10/2008_288137.
42. Corruption Perceptions Index, Transparency International,; 2011. http://cpi.transparency.org/cpi2011/results/.